Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesExpression of Multidrug Resistance Associated Protein 5 (MRP5) on Cornea and Its Role in Drug Efflux
Journal of Ocular Pharmacology and Therapeutics, 03/27/09
Karla PK et al. - Taken together immunolocalization on human cornea, in vitro efflux in human corneal and MRP5 over expressing cells, ex vivo and in vivo studies in intact cornea suggest that MRP5 on cornea can significantly lower the permeability of antiviral and glaucoma drugs. These findings may be valuable in developing formulation strategies to optimize ocular bioavailability of topically administered ocular agents.
Related Articles
Donor Risk Factors for Graft Failure in the Cornea Donor Study
Cornea, 10/14/09
Relevance Score: 91%
Relation between Axial Length and Ocular Parameters
Ophthalmologica, 10/28/09
Relevance Score: 89%
Evaluation of Keratometric, Pachymetric, and Elevation Parameters of Keratoconic Corneas With Pentacam
Cornea, 10/14/09
Relevance Score: 89%
Customized Aspheric Treatment Zone Ablation to Treat Irregular Corneas After Corneal Refractive Surgery
Journal of Refractive Surgery, 10/23/09
Relevance Score: 87%
In-vivo confocal microscopy reveals cellular-level detail of lymph vessels in live, unlabelled corneas
Investigative Ophthalmology and Visual Science, 10/15/09
Relevance Score: 87%
Today in Drug Resistance...keeping you current
Receive free subspecialty "5-minute updates" via email
Reduction of blood pressure in patients with treatment-resistant hypertension
Expert Opinion in Pharmacotherapy, 12/09/09
Linezolid in the Treatment of Multidrug-Resistant Tuberculosis
Clinical Infectious Diseases, 12/08/09
Efficacy and Safety of Efalizumab in Patients with Moderate-to-Severe Plaque Psoriasis Resistant to Previous Anti-Psoriatic Treatment: Results of a Multicentre, Open-label, Phase IIIb/IV Trial
Archives of Drug Information, 12/08/09
Sponsor
Article Search
Sponsor
Sponsor